Financial News · Live Terminal

Page 181 of 316

Research Alert: Tempus Ai Surpasses Q1 Expectations, Sales Guidance Raised

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Tempus AI reported Q1 2026 revenue of $348.1M (+36.1% Y/Y), beating the $345M consensus as both Diagnostics ($261.1M, +34.7%) and Data & Applications ($87.0M, +40.5%) segments delivered robust growth. Adjusted EPS of ($0.13) significantly outperformed the ($0.20) consensus and ($0.24) prior year result, while adjusted EBITDA improved $13.3M to ($2.8M) and adjusted gross margin reached 65.0% (up 360 bps Y/Y). Strong volume growth included 28% in Oncology testing, 54% in Hereditary following the Ambry Genetics acquisition in Q1 2025 (7% organic), and 500% in MRD testing to 6,500 tests performed. Following the strong beat, TEM raised 2026 revenue guidance to $1.59B-$1.60B (approximately 25% growth) while maintaining adjusted EBITDA guidance of $65M. We believe TEM's first Investor Day scheduled for May 29, 2026 should provide additional insights on market dynamics and long-term growth expectations, supporting the company's trajectory toward sustained profitability.

$TEM

Research56d ago

Research Alert: Lyv Q1: Strong Revenue Growth, Record Deferred Revenue Despite Legal Accrual

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:LYV delivered strong Q1 2026 revenue growth of 12% to $3.8B, though a $450M legal accrual resulted in operating loss of $(370.5)M and EPS impact of $(1.93), while underlying adjusted operating income grew 9% to $371M. The company demonstrated robust fundamentals with record deferred revenue reaching $6.6B for events (+22%) and $368M for ticketing (+29%), providing strong visibility with over 107M tickets sold for 2026 concerts (+11%). We believe LYV's venue expansion strategy continues delivering attractive returns, with recent acquisitions adding 4M annual fan capacity and venues opened in 2025 on track for 20%+ IRRs by 2028. Management projects double-digit growth in operating income and AOI for full-year 2026. We think the company's strong deferred revenue position and robust ticket sales provide a solid foundation for future growth, supported by planned capex of $1.1B-$1.2B for venue expansion. LYV maintains healthy liquidity with $9.1B cash and debt leverage at 3.6x.

$LYV

Research56d ago

Research Alert: Cc Posts Mixed Q1, Focus Is On Growth, Profitability, And Debt Reduction

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Chemours posted mixed Q1 results, with sales of $1.381B (+1% Y/Y), $20M below expectations, while adjusted EPS of $0.05 beat by $0.09 but declined from $0.13 prior year. Net loss widened to $29M from $5M due to higher financing costs and increased SG&A expenses. The results reflected significant segment divergence, with record TSS performance (+22% Y/Y to $568M) offsetting TT weakness (-6% Y/Y) and APM disruptions (-17% Y/Y). Management guided Q2 sequential sales growth of 15%-20% and full-year 2026 growth of 3%-5% Y/Y, with adjusted EBITDA of $800M-$900M. We view TSS's performance favorably due to Opteon refrigerant adoption and strong automotive Freon sales, achieving 33% adjusted EBITDA margin. However, we remain concerned about TT's margin compression to 3% from competitive pressures by lower-cost Asian producers and APM's operational challenges from Washington Works plant outage. We believe the deleveraging target to reduce net leverage from 4.9x to below 3.8x by year-end 2026 will be important.

$CC

Research56d ago

Research Alert: Logi Delivers Resilient Results Despite Middle East, Memory Supply Headwinds

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Q4 FY 26 results were near expectations with sales of $1.09B (+7% Y/Y) matching Street estimates while non-GAAP EPS of $1.13 (+22% Y/Y) slightly beat consensus of $1.10. Non-GAAP operating margin of 15.3% (+210 bps Y/Y) demonstrated impressive operational performance despite volatile cost pressures. Sales growth was broad-based with Gaming accelerating to 12% growth, Video Collaboration maintaining 13% expansion reinforcing B2B momentum, and sell-through exceeding reported sales by 400 bps overall. For Q1 FY 27, LOGI expects sales of $1.203B (+3% ex-FX) exceeding consensus of $1.14B and non-GAAP EPS of roughly $1.39 vs. $1.28 consensus. Management reiterated long-term mid-to-high single-digit organic growth with margins at the high end of 15-18% model, though FY 27 may see increased AI-related investments creating margin pressure. We think memory supply constraints may challenge the outlook but note resilient results in the meantime.

$LOGI

Research56d ago

Research Alert: Iff Q1 2026: Volume Growth Supports Quarterly Eps, Sales Beat

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:IFF delivered solid Q1 2026 results with net sales declining 4% Y/Y to $2.74B (above $2.64B consensus) primarily from completed divestitures, though comparable currency-neutral sales grew 3% with broad-based volume expansion. Adjusted EPS improved to $1.25 from $1.20, beating $1.07 consensus on operational efficiencies. We view the continued portfolio transformation as positive, with Taste delivering strong 18% comparable EBITDA growth and Health & Biosciences achieving 5% growth, though Scent faced margin pressure. Management maintained 2026 guidance of $10.5B-$10.8B sales and $2.05B-$2.15B adjusted operating EBITDA despite divestiture headwinds. We believe the $144M Y/Y free cash flow improvement to $92M and disciplined 2.5x net debt leverage demonstrate strong execution. The Food Ingredients divestiture progress, with Soy Crush business closing March 2, supports the strategic focus on higher-margin specialty solutions.

$IFF

Research56d ago

Research Alert: Lcid: Q1 Earnings Well Short Of Consensus; Cash Burn Accelerates

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Lucid Group (LCID) posted Q1 adjusted EPS of -$2.82 vs. -$2.04, well short of the -$2.30 consensus. Revenue rose 20% to $282.5M ($76.0M below consensus) in Q1, driven by higher prices, as total vehicle sales fell 1% to 3,093 units. Moreover, LCID's production/sales gap widened significantly, as the company produced 5,500 vehicles during the quarter. LCID's quarter-end cash and equivalents of $700M was down from $998M three months earlier, though total liquidity of approximately $3.2B provides near-term financial flexibility ($4.7B pro-forma for an April capital raise). In the release, LCID did not provide any update regarding prior 2026 vehicle production guidance of 25K-27K units, implying an increase over the 17,840 units produced in 2025. In our view, LCID's actual sales are of greater importance, given apparent demand-related issues. LCID shares are currently trading 2% lower after-hours. This was an ugly release with few positives, aside from the April capital raise which extends its liquidity runway.

$LCID

Research56d ago

Research Alert: Lumen Technologies Beats On Revenue, Set To Acquire Alkira For $475m

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Lumen Technologies reported Q1 2026 results with total revenue declining to $2.899B (-9% Y/Y) and diluted loss per share of $0.20, flat vs. the prior year, though excluding special items the loss widened to $0.47 from $0.13. The quarter marked a historic milestone as Strategic revenue reached 51% of business revenue at $1.246B (+9%), officially surpassing Legacy revenue of $1.198B (-14%) for the first time. This validates the transformation strategy, with strong NaaS momentum showing 25% Q/Q customer growth and a 32% increase in services sold. Management completed the Mass Markets divestiture generating $4.977B and announced the Alkira acquisition to accelerate digital capabilities. The company raised 2026 free cash flow guidance to $1.9B-$2.1B from $1.2B-$1.4B, reflecting divestiture proceeds. We expect business revenue to inflect to growth in 2028 as Strategic revenues become dominant, and we will look for NaaS adoption metrics as leading indicators of digital transformation progress.

$LUMN

Research56d ago

Research Alert: Pru Q1 Eps Tops Expectations But Japan Sales Suspension Is An Overhang

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PRU reported Q1 2026 operating EPS of $3.61, up from $3.29 and beating our $3.18 estimate and the $3.11 consensus view. Net income declined 16% to $597M due to $621M in pretax investment losses versus $246M in the prior-year quarter. The quarter was overshadowed by PRU's April extension of the Prudential of Japan sales suspension to address ongoing employee misconduct issues first identified earlier in 2026. PGIM delivered strong 22% growth in adjusted operating income to $190M, with AUM reaching $1.433T, while U.S. businesses posted modest 3% growth to $956M led by 9% Retirement segment growth. International businesses declined 4% to $810M primarily due to Japan suspension-related expenses, though other international markets demonstrated resilience. We view the extended Japan sales suspension as a material negative catalyst that removes upside potential from the shares despite otherwise solid operational performance across PRU's diversified business segments.

$PRU

Research56d ago

Research Alert: Davita: Q1 Eps Beat With Margin Improvement Despite Dialysis Volume Headwinds

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:DaVita delivered strong Q1 2026 results with adjusted EPS of $2.87, up 43.5% and well above the $2.33 consensus forecast, driven by higher reimbursement rates and continued aggressive share repurchases. Revenue increased 6.0% to $3.416B despite treatment volume headwinds, with U.S. dialysis revenue per treatment rising $17.45 to $417.59 reflecting higher reimbursement rates. The solid performance demonstrates operational resilience despite challenging normalized non-acquired treatment volume growth of just 0.1%. Management raised adjusted EPS guidance to $14.10-$15.20 from the prior $13.60-$15.00 range. Operating margin improved 50 basis points to 14.1% though compressed 140 basis points sequentially due to seasonal trends, while free cash flow surged to $140M from -$45M in the prior year quarter. The company maintained FCF guidance at $1.0B-$1.25B, supporting continued return of capital to shareholders, in our view.

$DVA

Research56d ago

Research Alert: Tdc Posts Q1 Beats As Public Cloud Arr Grew 13% Y/y

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:TDC reported Q1 non-GAAP EPS of $0.88, beating consensus by $0.11, while total revenue of $444M grew 6% Y/Y, ahead of expectations by $14M. GAAP EPS of $3.47 was boosted by a $359M pre-tax benefit from the SAP litigation settlement, which provided $480M in gross proceeds. Strong cloud momentum continued with public cloud ARR growing 13% Y/Y to $686M, while total ARR reached $1.492B, up 3% Y/Y, demonstrating continued stabilization in the recurring revenue base. Management expects Q2 recurring revenue of -2% to flat Y/Y and total revenue of -4% to -2% Y/Y, suggesting near-term quarterly moderation. However, full-year 2026 guidance was largely reaffirmed with total ARR growth of 2%-4% and non-GAAP EPS of $2.55-$2.65, while cash flow guidance increased to $642M-$662M. We believe the significant margin expansion, with non-GAAP operating margin up 550 bps to 27.3%, reflects strong operational leverage and effective cost discipline as the company continues optimizing its structure.

$TDC

Research56d ago

Research Alert: Solventum: Broad-based Q1 Growth, Guidance Maintained

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:SOLV delivered Q1 adj. EPS of $1.48 (+10.6% Y/Y), beating consensus of $1.35, while reported sales declined 3.0% Y/Y to $2.0B due to the Purification and Filtration divestiture, though organic sales grew 2.1%. Segment performance was broadly supportive, with Advanced Wound Care posting 10.9% reported growth (benefiting from the December Acera acquisition) and 2.1% organic growth, Dental Solutions achieving 3.4% organic growth, Health Information Systems delivering 4.7% organic growth, and core MedSurg (61% of sales) growing 1.2% organically. Management reaffirmed full-year 2026 guidance with confidence, expecting organic sales growth of 2.0% to 3.0% and adj. EPS toward the high end of the $6.40 to $6.60 range. Adj. gross margin improved 80 bps Y/Y to 56.4%, though adj. operating margin compressed 20 bps to 19.5% as tariff and inflation pressures offset operational improvements. Operating cash flow turned negative at $(189)M vs $29M prior year, though management maintains full-year guidance of ~$200M.

$SOLV

Research56d ago

Research Alert: Jkhy Delivers Strong Mar-q Beat On Accelerating Core Wins And Payments Growth

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:JKHY reported strong Mar-Q results, with GAAP EPS of $1.71 vs. $1.52 prior year, beating consensus by $0.22, while revenue of $636M (+9%) exceeded the Street estimate of $619M. Balanced segment performance included Services and Support advancing 10% and Processing growing 7%, with high-growth areas driving momentum as faster payments revenue surged 46% and digital/transaction revenue expanded 10%. The company secured 17 competitive core deals in Mar-Q, representing the best third-quarter performance for new core wins in seven years, reflecting strong market recognition of JKHY's technology roadmap. Operating leverage remained evident, with adjusted operating income increasing 7% to $141M, while maintaining stable operating margin at 22.9%. The balance sheet showed continued deleveraging, with total debt declining to $90M from $170M prior year, and the company generated strong operating cash flow of $459M YTD while deploying $284M in share repurchases, demonstrating confidence in the business outlook.

$JKHY

Research56d ago

Research Alert: Strategy Results: Btc Yield Of 9.4% Ytd With 63,410k Btc Acquired In Q1

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:MSTR reported a $14.5B operating loss in Q1 2026 due to BTC value declines, though achieved a strong 9.4% BTC Yield YTD by gaining 63,410 BTC. The company purchased 89,599 bitcoins during Q1 at an average price of $80,929, deploying $7.25B in capital and bringing total Q1 holdings to 762,099 BTC. MSTR's aggressive BTC accumulation strategy continues to drive significant balance sheet expansion, with total holdings reaching 818,334 BTC as of May 3 at a $75,537 per BTC cost basis totaling $61.81B. The company successfully raised $7.37B through at-the-market offerings during the quarter, including $5.30B from common stock sales and $2.07B from STRC preferred stock issuances. BTC holdings grew 22% Y/Y, while the balance sheet reflects $2.21B in cash and cash equivalents, $8.2B in long-term debt, and $8.98B in Series A perpetual preferred stock, demonstrating the company's continued reliance on capital markets to fund its Bitcoin treasury strategy.

$MSTR

Research56d ago

Research Alert: Slab Q1 Shows Marked Improvement; Pending Acquisition Still Progressing

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Silicon Labs delivered strong Q1 2026 results with revenue of $213M (+20% Y/Y), marking growth acceleration, while non-GAAP EPS of $0.53 represented improvement from the $(0.48) GAAP loss per share. Industrial & Commercial revenue surged 33% to $128M and Home & Life grew 5% to $86M, driven by strength in electronic shelf labels, smart metering, and medical applications (+21%). The diversified IoT exposure and 59.7% non-GAAP gross margin expansion highlight operational leverage. Management suspended forward guidance due to the TI acquisition but noted accelerating bookings throughout the quarter, particularly in broad industrial business. Design wins exceeded internal targets and 2025's record run rate, while the book-to-bill ratio reached multi-year highs and declining distributor inventories support near-term visibility. With $383M in cash and strengthening demand across diversified IoT verticals, the company appears well-positioned for continued growth.

$SLAB

Research56d ago

Research Alert: Lite Tops Estimates Amid Ai Data Center Boom, Record Revenue, Margin Expansion

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Lumentum delivered exceptional Q3 FY26 results with record revenue of $808.4M (+21.5% Q/Q, +90.1% Y/Y) and non-GAAP EPS of $2.37, demonstrating remarkable operating leverage. Non-GAAP operating margins expanded 700 bps Q/Q to 32.2%, validating management's scaling strategy to meet hyperscaler demand. Both Components ($533.3M, +20.2% Q/Q) and Systems ($275.1M, +24.0% Q/Q) segments delivered robust growth, reflecting comprehensive positioning across AI infrastructure. Management's optimistic Q4 guidance signals sustained momentum with revenue midpoint of $985M (~22% Q/Q growth) and operating margins expanding to 35.0%-36.0%. The company remains sold out with significant supply-demand imbalance, undershipping customer demand by ~30% despite 40% capacity expansion progress. We believe the scalability of Lumentum's photonics platform positions it well to capitalize on AI buildout, with all EML capacity covered by LTAs through 2027 providing revenue visibility and pricing stability.

$LITE

Research56d ago

Research Alert: Match Group Q1 Beat; Tinder Engagement Inflects

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Match Group delivered Q1 results with revenue of $864M (+4% Y/Y) beating consensus of $854M, while adjusted EBITDA of $343M (+25%) significantly exceeded the $317M estimate, reflecting improved operational discipline. The quarter's most encouraging development was Tinder's turnaround momentum, with engagement metrics showing improvement including Sparks Coverage up 6% Y/Y and MAU declines moderating to 7%, the slowest pace in 31 months. Management provided Q2 guidance of $850-860M, incorporating expected headwinds from Tinder user experience testing and continued Azar pressure. Hinge continued strong scaling with 28% revenue growth to $194M, advancing toward its $1B target. We believe the engagement improvements at Tinder validate the transformation thesis, though monetization translation remains gradual with revenue growing just 2% Y/Y. The company's efficiency initiatives support the path toward Resurgence, targeting Tinder's return to growth in 2027.

$MTCH

Research56d ago

Research Alert: Dvn: A Q1 Miss, But Coterra Merger Looms

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:DVN posted Q1 adjusted EPS of $1.04 vs $1.21 prior year, missing consensus by $0.05. Production of 833k boe/d grew from 815k in Q1 2025 but came in 3k below expectations. Capex of $848M was 6% below the guidance midpoint, driving robust FCF of $816M, up 16% sequentially. The pending Coterra merger, approved by shareholders on May 4 and closing May 7, represents a significant catalyst with management targeting $1B in annual pretax synergies by year-end 2027. DVN's business optimization plan is accelerating, with the full $1B annual pretax improvement target expected well ahead of schedule. The Delaware Basin anchored results with 501k boe/d (60% of total production), while DVN maintained a balanced 46% liquids/54% gas mix, positioning it well for merger integration. Post-merger, we expect enhanced shareholder returns through a planned $5B+ share repurchase authorization and quarterly dividend increase to $0.315/share, supported by a strong balance sheet with $1.8B in cash and a 0.9x net debt-to-EBITDAX.

$DVN

Research56d ago

Research Alert: Celanese Misses Q1 Consensus Estimates, Provides Optimistic Q2 Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CE reported Q1 2026 EPS of $0.85 vs. $0.54 in the prior year, missing consensus by $0.05, while revenue of $2.337B rose 6% sequentially but declined 2% Y/Y, missing estimates by $9M. Engineered Materials showed strong operational improvements with sales of $1.325B (+3% Y/Y) and operating margins expanding to 17% as operating profit surged to $221M from $94M, reflecting successful execution of product mix optimization and cost reduction initiatives. Management advanced structural actions including closure of the Singapore nylon facility and network enhancements across Asia and Europe. Management raised full-year FCF guidance to $700M-$800M and provided Q2 EPS guidance of $2.00-$2.40, with approximately $3.00 expected for the second half. The company targets net debt/operating EBITDA improvement to 4.8x through continued cash generation, though Q1 FCF of only $3M reflects seasonal working capital timing and highlights the importance of debt reduction given elevated leverage levels.

$CE

Research56d ago

Research Alert: Eog: A Q1 Eps Beat, But Cost Pressures Abound

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:EOG posted Q1 adjusted EPS of $3.41 vs. $2.87, beating consensus by $0.20. Production surged 27% to 1.38M boe/d, with natural gas volumes up 45% to 3.02 Bcf/d and NGL volumes rising 37%, driven by the Encino acquisition which closed in Q3 2025 for $4.45B, expanding EOG's Utica Shale position. We view the transformative deal as strengthening EOG's portfolio and growth trajectory, though cost pressures are evident as gathering and transportation expenses rose 49% to $654M reflecting operational integration challenges. Natural gas pricing improved 10% to $3.76/MMBtu while crude remained flat at $72.47/barrel. Free cash flow remained robust at $1.49B despite higher capex of $1.64B. EOG's net debt position shifted to $4.08B, representing an 11.7% net debt-to-total capitalization ratio. We note this remains considerably better than our E&P peer average of 25%, providing EOG with financial flexibility while capturing substantial growth potential from its expanded asset base, in our view.

$EOG

Research56d ago

Research Alert: Smci: Q3 Sees Margin Recovery But Revenue Miss; Cash Outflows Strain Liquidity

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Q3 FY 26 results were mixed as revenue of $10.24B (+123% Y/Y) missed consensus expectations of $12.45B, though non-GAAP EPS of $0.84 easily beat the $0.62 estimate. Gross margin recovered meaningfully to 9.9% (+30 bps Y/Y, +370 bps Q/Q) from Q2's record low of 6.3%. These mixed results may give investors pause, especially with the sales miss and ongoing credibility risks following export control violations by former senior management, raising questions in our view. Q4 guidance calls for revenue of $11.0B-$12.5B (midpoint $11.75B vs. Street $11.31B) and non-GAAP EPS of ~$0.72 vs. consensus $0.56. We are nervous about the company's strained liquidity position as cash declined to $1.29B from $4.09B while debt increased to $8.8B from $4.9B, driven by $6.6B in operating cash outflows (vs. $1.9B expected) primarily from $10B in accounts payable payments. We expect additional pressure from inventory buildup for the Blackwell platform ramp amid export control fines and working capital requirements.

$SMCI

Showing 3601-3620 of 6317